On March 4, 2024, Zencore Biologics Co., Ltd. (Zencore Biologics) and Apeloa Pharmaceutical Co.,Ltd (Apeloa Pharmaceutical) have signed a strategic cooperation agreement covering collaborative research and development and production in the field of Antibody-drug Conjugates (ADCs). The agreement aims to leverage the respective domestic and international business advantages and resources of both parties to jointly build a next-generation ADC research and production service platform.

Chairman of Apeloa Pharmaceutical, Mr. Fangmeng Zhu (left) 

Chairman of Zencore Biologic, Mr. Chen Jianxin (right)